Navigation Links
PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
Date:3/6/2008

ANNAPOLIS, Md., March 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it has completed the initial pharmacokinetic (PK) testing of Protexia(R), the Company's broad spectrum chemical nerve agent prophylaxis.

The PK studies were conducted in two animal species and used the final pegylated version of rBChE for the first time. In general, the conjugation of proteins with polyethylene glycol (PEG) has been shown to decrease immunogenicity, increase circulating serum half-life and increase stability of recombinant proteins. The data from these studies confirm that the specific PEG chosen for conjugation to rBChE will significantly improve the half-life of the protein in vivo.

The PK studies demonstrated that Protexia(R) had a half life of approximately four days in primates and three days in rodents when administered by intramuscular injection. These data compare favorably with what was predicted for the drug's PK profile in these animal species.

John Troyer, Ph.D., Senior Program Director for Protexia(R), commented, "These results are very meaningful in that they show that Protexia(R) meets or exceeds our target product profile for use as a chemical nerve agent prophylaxis. The impressive half life data also confirm that the pegylation of rBChE as part of our manufacturing process achieved the goal of extending the half-life of the protein to one which makes it a feasible product for use in humans."

Dr. Troyer continued, "Having successfully completed the PK studies, we are on target to complete our toxicology studies and file the Investigational New Drug (IND) application for Protexia(R) in the third quarter of 2008; we expect to commence Phase I human safety testing of Protexia(R) in the fourth quarter."

"Today's announcement highlights the intense commitment and stro
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
8. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Carrington Completes $8 Million Financing
11. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... , SANTA CLARA, Calif., Dec. 7 Cell Biosciences, ... Inc. of Lexington, Massachusetts, a leader in sample preparation ... acquisition adds Protein Forest,s novel digital ProteomeChip(TM) product line ... protein analysis. , Protein Forest, founded in 2002, pioneered ...
... , , RESEARCH TRIANGLE PARK, N.C., ... innovative treatments for diseases of the central nervous system, today announced ... that CeNeRx,s novel compound TriRima (TM) reversibly inhibits MAO-A (monoamine ... role in the regulation of mood. TriRima is ...
... ... Pollogen received ANVISA approval to market the TriPollar Technology- the most advanced ... anti-aging products have been clinically proven the world over to be ... and non-invasive and patients enjoy visible results from the very 1st treatment. ...
Cached Biology Technology:Cell Biosciences Acquires Protein Forest 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
(Date:7/11/2014)... members to reduce aggression and gain access to scarce ... activities shows a certain pattern across the day. The ... Biology Letters . , Grooming between individuals in a ... To be groomed has hygienic benefits and is stress ... provide access to infants, mating opportunities and high quality ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... was the credo of early 20th century architects making design ... biologists may be turning that on its head. New research* ... and Technology (NIST) reinforces the idea that stem cells can ... by controlling their shape. The results may be important to ...
... of Health (NIH) has awarded a five-year $23.2 million ... and the University of Medicine and Dentistry of New ... research aimed at developing drug products that could be ... Members of the Environmental and Occupational Health Sciences ...
... A protein critical in heart development may also play ... by investigators from Vanderbilt-Ingram Cancer Center and the Vanderbilt Eye ... which also is key in regulating corneal cells ... , The study, appearing in the October issue of ...
Cached Biology News:Shaping up: Controlling a stem cell's form can determine its fate 2Rutgers, UMDNJ receive $23 million to develop antidotes for chemical weapons attacks 2Protein found in heart may be target for colon cancer therapies 2Protein found in heart may be target for colon cancer therapies 3
Handles samples from from 75l to 150l...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Ubiquitin Related I Sampler Kit 10 mu g each...
DNA Repair Sampler Kit 10g each...
Biology Products: